# Study of Jitongning Tablet to Treat Spondyloarthritis

> **NCT03932019** · PHASE2 · COMPLETED · sponsor: **Tasly Pharmaceutical Group Co., Ltd** · enrollment: 238 (actual)

## Conditions studied

- Spondyloarthritis

## Interventions

- **DRUG:** Jitongning tablet(High-dose )
- **DRUG:** Jitongning tablet(Low-dose )
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03932019
- **Lead sponsor:** Tasly Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-11
- **Primary completion:** 2021-06-20
- **Final completion:** 2021-08-20
- **Target enrollment:** 238 (ACTUAL)
- **Last updated:** 2022-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03932019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03932019, "Study of Jitongning Tablet to Treat Spondyloarthritis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03932019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*